Unique ID issued by UMIN | UMIN000008632 |
---|---|
Receipt number | R000010143 |
Scientific Title | Phase II study of a Combination of Paclitaxel and 5'-DFUR in Patients with S-1 Failure Unresectable or Recurrent Gastric Cancer |
Date of disclosure of the study information | 2012/08/06 |
Last modified on | 2013/09/09 12:54:58 |
Phase II study of a Combination of Paclitaxel and 5'-DFUR in Patients with S-1 Failure Unresectable or Recurrent Gastric Cancer
Phase II study of a Combination of Paclitaxel and 5'-DFUR in Patients with S-1 Failure Unresectable or Recurrent Gastric Cancer
Phase II study of a Combination of Paclitaxel and 5'-DFUR in Patients with S-1 Failure Unresectable or Recurrent Gastric Cancer
Phase II study of a Combination of Paclitaxel and 5'-DFUR in Patients with S-1 Failure Unresectable or Recurrent Gastric Cancer
Japan |
Advanced or recurrent gastric cancer previously treated with S-1
Gastroenterology | Gastrointestinal surgery |
Malignancy
NO
To evaluate clinical usefulness of combination chemotherapy with weekly paclitaxel and 5'-DFUR in S-1 failure advanced or recurrent gastric cancer.
Safety,Efficacy
Confirmatory
Pragmatic
Phase II
Response Rate
Overall survival(OS), Progression-free survival(PFS), Time to Treatment Failure(TTF), Adverse Effect, QOL
Interventional
Single arm
Non-randomized
Open -no one is blinded
Uncontrolled
1
Treatment
Medicine |
The treatment included PTX 70 mg/m2 i.v. on days 1, 8, and 15 every 4 weeks and 5'-DFUR 600 mg/body p.o. everyday
20 | years-old | <= |
Not applicable |
Male and Female
1) Histologically proven unresectable or recurrent gastric cancer showing resistance to S-1.
2) ECOG Performance status:0-2
3) Up to one prior chemotherapy
4) 4 weeks rest after prior chemotherapy
5) Measurable disease or non-measurable but assessable disease according to the Response Evaluation Criteria in Solid Tumors. (RECIST)
6) Adequate organ functions:
i) hemoglobin >=9.0g/dL,
ii) WBC >=4000/mm3,
iii) neutrophils >=2000/mm3,
iv) platelets >=100,000/mm3,
v) AST(GOT)/ALT(GPT) <=2.5 X UL,
vi) total bilirubin <=1.5mg/dL,
vii) creatinine <=1.5mg/dL,
7) Life expectancy of more than 3 months
8) Age greater than 20
9) Informed consent approved by IRB
1) Drug hypersensitivity.
2) Infection and inflammation.
3) Prior infusion of paclitaxel
4) Peripheral neuropathy
5) Active synchronous malignancy.
6) Brain metastasis.
7) Severe mental disorders.
8) Symptomatic pulmonary fibrosis or interstitial pneumonia.
9) Severe systemic edema.
10) A large amount of pleural effusion or peritoneal fluid.
11) Severe heart disease.
12) Myocardial infarction within six months.
13) DM with insulin injection.
14) Pregnant patient
35
1st name | |
Middle name | |
Last name | Masaaki Oka |
Yamaguchi University Graduate School of Medicine
Department of Digestive Surgery and Surgical Oncology
1-1-1 Minamikokushi, Ube, Yamaguchi 755-8505, Japan
0836-22-2264
sigefumi@yamaguchi-u.ac.jp
1st name | |
Middle name | |
Last name | Shigefumi Yoshino |
Yamaguchi University Graduate School of Medicine
Department of Digestive Surgery and Surgical Oncology
1-1-1 Minamikokushi, Ube, Yamaguchi 755-8505, Japan
0836-22-2264
sigefumi@yamaguchi-u.ac.jp
Department of Digestive Surgery and Surgical Oncology, Yamaguchi University Graduate School of Medicine
Department of Digestive Surgery and Surgical Oncology, Yamaguchi University Graduate School of Medicine
Other
NO
2012 | Year | 08 | Month | 06 | Day |
Partially published
Open public recruiting
2007 | Year | 09 | Month | 20 | Day |
2007 | Year | 10 | Month | 01 | Day |
2012 | Year | 08 | Month | 06 | Day |
2013 | Year | 09 | Month | 09 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000010143